Fennec Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Fennec Pharmaceuticals has been growing earnings at an average annual rate of 8.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 90.3% per year.
Key information
8.6%
Earnings growth rate
13.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 90.3% |
| Return on equity | n/a |
| Net Margin | -2.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Nov 24
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
Oct 04Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Revenue & Expenses Breakdown
How Fennec Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 49 | -1 | 44 | 0 |
| 30 Jun 24 | 49 | 3 | 41 | 0 |
| 31 Mar 24 | 45 | 3 | 37 | 0 |
| 31 Dec 23 | 21 | -16 | 33 | 0 |
| 30 Sep 23 | 13 | -20 | 29 | 0 |
| 30 Jun 23 | 7 | -26 | 29 | 1 |
| 31 Mar 23 | 3 | -26 | 25 | 2 |
| 31 Dec 22 | 2 | -24 | 21 | 4 |
| 30 Sep 22 | 0 | -21 | 17 | 4 |
| 30 Jun 22 | 0 | -17 | 13 | 4 |
| 31 Mar 22 | 0 | -16 | 12 | 4 |
| 31 Dec 21 | 0 | -17 | 12 | 5 |
| 30 Sep 21 | 0 | -16 | 11 | 6 |
| 30 Jun 21 | 0 | -18 | 12 | 6 |
| 31 Mar 21 | 0 | -19 | 13 | 6 |
| 31 Dec 20 | 0 | -18 | 13 | 5 |
| 30 Sep 20 | 0 | -18 | 13 | 5 |
| 30 Jun 20 | 0 | -14 | 10 | 4 |
| 31 Mar 20 | 0 | -14 | 9 | 5 |
| 31 Dec 19 | 0 | -13 | 7 | 6 |
| 30 Sep 19 | 0 | -12 | 6 | 6 |
| 30 Jun 19 | 0 | -13 | 6 | 7 |
| 31 Mar 19 | 0 | -11 | 5 | 6 |
| 31 Dec 18 | 0 | -10 | 5 | 5 |
| 30 Sep 18 | 0 | -9 | 6 | 4 |
| 30 Jun 18 | 0 | -9 | 6 | 3 |
| 31 Mar 18 | 0 | -8 | 6 | 2 |
| 31 Dec 17 | 0 | -7 | 5 | 2 |
| 30 Sep 17 | 0 | -6 | 4 | 1 |
| 30 Jun 17 | 0 | -4 | 3 | 1 |
| 31 Mar 17 | 0 | -3 | 3 | 1 |
| 31 Dec 16 | 0 | -3 | 2 | 0 |
| 30 Sep 16 | 0 | -2 | 2 | 0 |
| 30 Jun 16 | 0 | -2 | 2 | 0 |
| 31 Mar 16 | 0 | -1 | 2 | 0 |
| 31 Dec 15 | 0 | -1 | 2 | 0 |
| 30 Sep 15 | 0 | 1 | 2 | 0 |
| 30 Jun 15 | 0 | 2 | 2 | 0 |
| 31 Mar 15 | 0 | 1 | 2 | 0 |
| 31 Dec 14 | 0 | -2 | 3 | 0 |
| 30 Sep 14 | 0 | -2 | 2 | 0 |
| 30 Jun 14 | 0 | -5 | 2 | 0 |
Quality Earnings: FENC is currently unprofitable.
Growing Profit Margin: FENC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FENC is unprofitable, but has reduced losses over the past 5 years at a rate of 8.6% per year.
Accelerating Growth: Unable to compare FENC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FENC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: FENC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 02:56 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fennec Pharmaceuticals Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Naureen Quibria | Capital One Securities, Inc. |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |